Citigroup Maintains Buy on Cogent Biosciences, Raises Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst David Lebowitz maintains a Buy rating on Cogent Biosciences and raises the price target from $13 to $15.
September 24, 2024 | 4:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Citigroup's analyst David Lebowitz has reiterated a Buy rating for Cogent Biosciences and increased the price target from $13 to $15, indicating a positive outlook for the company's stock.
The increase in price target from $13 to $15 by Citigroup suggests a positive outlook for Cogent Biosciences, likely leading to a short-term increase in stock price. The Buy rating indicates confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100